As there is no clinically applicable PC inhibitor available and MPC1/2 inhibition should replicate its effect, we next tested the impact of combining MSDC-0160 with imatinib on colony formation potential of CML CD34+ cells isolated from six CML patients. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.